DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH
NCT05164978
·
clinicaltrials.gov ↗
NA
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Hemophagocytic Lymphohistiocytosis
Interventions
DRUG:
DEP combine with PD-1 antibody
Sponsor
Beijing Friendship Hospital